Bank of America Boosts Shire (SHPG) Price Target to $237.00

Shire (NASDAQ:SHPG) had its price objective raised by analysts at Bank of America from $236.00 to $237.00 in a research note issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America’s price target points to a potential upside of 73.77% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the stock. BidaskClub cut shares of Shire from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Piper Jaffray Companies reiterated a “hold” rating and set a $160.00 price objective on shares of Shire in a research report on Friday, October 27th. Royal Bank of Canada reiterated a “buy” rating on shares of Shire in a research report on Thursday, November 16th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, Liberum Capital reiterated a “hold” rating on shares of Shire in a research report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. Shire has an average rating of “Hold” and an average price target of $214.25.

Shire (NASDAQ SHPG) traded down $2.80 during mid-day trading on Monday, hitting $136.39. 464,663 shares of the stock traded hands, compared to its average volume of 1,423,755. The company has a market capitalization of $42,570.00, a P/E ratio of 25.59, a P/E/G ratio of 0.75 and a beta of 1.41. Shire has a 12-month low of $135.22 and a 12-month high of $192.15. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.

A number of large investors have recently bought and sold shares of the business. Gabelli Funds LLC grew its holdings in Shire by 4.7% in the fourth quarter. Gabelli Funds LLC now owns 74,500 shares of the biopharmaceutical company’s stock worth $11,556,000 after purchasing an additional 3,332 shares during the period. SeaCrest Wealth Management LLC acquired a new stake in Shire in the fourth quarter worth $107,000. Aperio Group LLC grew its holdings in Shire by 11.7% in the fourth quarter. Aperio Group LLC now owns 93,655 shares of the biopharmaceutical company’s stock worth $14,528,000 after purchasing an additional 9,786 shares during the period. Telemus Capital LLC acquired a new stake in Shire in the fourth quarter worth $350,000. Finally, Boston Partners grew its holdings in Shire by 60.9% in the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after purchasing an additional 886,572 shares during the period. Institutional investors and hedge funds own 20.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Bank of America Boosts Shire (SHPG) Price Target to $237.00” was originally reported by American Banking and Market News and is the property of of American Banking and Market News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/05/bank-of-america-boosts-shire-shpg-price-target-to-237-00.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.